drug_type
RELEVANT_DRUG
intervention_type
Monoclonal antibody (biologic)
drug_description
Recombinant humanized IgG1 monoclonal antibody targeting HER2/ERBB2 (subdomain II). It blocks ligand-induced heterodimerization with EGFR/HER3/HER4, inhibiting downstream PI3K/AKT and MAPK/ERK signaling and reducing tumor cell proliferation/survival; also engages Fcγ receptors to mediate ADCC. In this trial, a biosimilar pertuzumab is compared with the reference product Perjeta (pertuzumab), both given intravenously.
nci_thesaurus_concept_id
C38692
nci_thesaurus_preferred_term
Pertuzumab
nci_thesaurus_definition
A humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the HER-2 tyrosine kinase receptor. Binding of the antibody to the dimerization domain of the HER-2 tyrosine kinase receptor protein directly inhibits the ability of the HER-2 tyrosine kinase receptor protein (the most common pairing partner) to dimerize with other HER tyrosine kinase receptor proteins; inhibiting receptor protein dimerization prevents the activation of HER signaling pathways, resulting in tumor cell apoptosis. (NCI04)
drug_mesh_term
pertuzumab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized IgG1 monoclonal antibody that binds the HER2/ERBB2 extracellular dimerization domain (subdomain II), preventing HER2 heterodimerization with EGFR/HER3/HER4, thereby inhibiting downstream PI3K/AKT and MAPK/ERK signaling and reducing tumor cell proliferation and survival; additionally engages Fc gamma receptors to mediate ADCC.
drug_name
Pertuzumab
nct_id_drug_ref
NCT05825781